As January 2026 unfolds, Asian markets are exhibiting a mix of optimism surrounding artificial intelligence advancements and cautious economic growth forecasts, particularly in China and Japan. Amidst this backdrop, investors are keenly focused on identifying undervalued stocks, which could present unique opportunities to leverage market inefficiencies.
The following companies have emerged as notable prospects based on their current stock prices compared to estimated fair values:
-
Visional (TSE:4194): Priced at ¥10,010.00, with a fair value estimated at ¥19,887.98, this stock is trading at a 49.7% discount.
-
Takara Bio (TSE:4974) offers a similar picture; currently valued at ¥795.00 against a fair value of ¥1,580.06, indicating a 49.7% discount.
-
Other notable mentions include Nan Juen International (TPEX:6584), Kuraray (TSE:3405), and JINS HOLDINGS (TSE:3046), all demonstrating discounts ranging from 49.5% to 49.9%.
Investors can explore a more extensive list of 260 undervalued stocks sourced from a cash flows screener, but a deeper look at a few prime choices reveals more about the potential opportunities in the market.
CLASSYS Inc.
This company, specializing in medical aesthetics devices, holds a market capitalization of ₩3.56 trillion. Its revenue primarily stems from the Surgical & Medical Equipment segment, generating ₩317.80 billion. CLASSYS is currently trading at ₩54,053.53, approximately 42% below its estimated fair value of ₩94,028.53. Despite a slight decline in sales for Q3 of 2025, net income has more than doubled year-on-year, with earnings growth at 39.1% over the past year, expected to continue at an impressive annual rate of 30.9%. Analysts anticipate a potential price increase of about 33.8%.
Beiqi Foton Motor Co., Ltd.
Operating within the commercial vehicle manufacturing sector, Beiqi Foton holds a market cap of CN¥23.12 billion. The company is trading at CN¥2.92, significantly lower than its estimated fair value of CN¥4.43, indicating a 34% discount. Over the past year, its earnings have surged by 37.6%, with projections for annual growth at 39.14%, well above the average growth rate of 27.5% anticipated in the Chinese market. Foton’s recent advancements in new energy vehicle platforms underline its dedication to sustainable logistics, potentially bolstering future profitability.
Xiamen Amoytop Biotech Co., Ltd.
This firm is engaged in the research, development, production, and sale of recombinant protein drugs in China and internationally, boasting a market cap of CN¥34.16 billion. Currently priced at CN¥83.68, it is trading well below an estimated fair value of CN¥162.36, indicating a potential undervaluation of approximately 48.5%. The company reported an earnings growth of 26.9% in the past year and is expected to see annual growth of 34.1%, surpassing the average growth rate of 27.5% in the Chinese market. Strong revenue growth alongside a high return on equity forecast could enhance its financial performance in the future.
For those interested in a more comprehensive perspective on undervalued Asian stocks based on cash flows, a detailed list is available via an online screener.
Investors are also encouraged to stay updated on developments in their portfolios by utilizing investment tracking applications designed to alert them to significant stock changes. Such tools cater primarily to long-term investors, and while the commentary provided offers insights based on historical data and forecasts, it’s essential to conduct thorough research tailored to individual financial goals and risk appetites.
